Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial.

APOE 4 non-carriers showed a trend toward greater CSF DHA levels and significantly greater EPA levels compared with APOE 4 carriers.

also in 53,322 other papers

With the exception of a nominally significant difference in change of scores in CVLT Trial 5 of list learning (DHA treated arm learned one additional word than the placebo treated arm), all other measures of cognition did not significantly differ between treatment arms. 4 Discussion In this trial, we sought to determine the levels of DHA and EPA in CSF following DHA supplementation in cognitively unimpaired individuals at risk of dementia, and whether the changes in CSF DHA and EPA levels are related to APOE 4 carrier status.

also in 7,732 other papers